Analyst firms · Leerink Partners · AXSM

Leerink Partners AXSM price target and rating history

Axsome Therapeutics Inc. (AXSM) · Health Care

Leerink Partners rates Axsome Therapeutics Inc. (AXSM) Outperform with a $50 price target, as of its latest action on Mar 2, 2022. It has published 3 rating actions on AXSM since August 2021, including 0 upgrades and 0 downgrades. Across 4 firms with a AXSM price target in the last 12 months, the median target is $257.50.

Current rating
Outperform
Price target
$50
Median target, all firms
$257.50
Actions on AXSM
3

Leerink Partners price target on AXSM

$75$63$5020222023202420252026
Leerink Partners price target on AXSM, each point a stated target, August 2021 to March 2022.

Every Leerink Partners rating on AXSM

How other firms rate AXSM

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Truist SecuritiesBuy$285Sep 23, 2026
BMO Capital MarketsOutperform$310Jul 21, 2026
Wolfe ResearchOutperform$230Feb 24, 2026
Morgan StanleyEqual-Weight$204Jan 8, 2026

Questions about Leerink Partners and AXSM

What is Leerink Partners's price target for AXSM?
Leerink Partners's latest stated price target for Axsome Therapeutics Inc. (AXSM) is $50, from its action on Mar 2, 2022.
What is Leerink Partners's rating on AXSM?
Leerink Partners rates AXSM Outperform, a bullish rating, as of Mar 2, 2022.
When did Leerink Partners last change its view on AXSM?
On Mar 2, 2022, Leerink Partners cuts its price target to $50 from $65, keeps Outperform.
How does Leerink Partners's AXSM target compare with other analysts?
Across 4 firms with a AXSM price target in the last 12 months, the median target is $257.50.

More AXSM rating histories

All Leerink Partners ratingsAXSM news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.